Vor Bio price target lowered to $13 from $17.50 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Vor Bio (VOR) to $13 from $17.50 and keeps a Buy rating on the shares after the company reported FY24 financial results and provided a corporate update. The company expects to present a clinical data update from Mylotarg-treated patients within the ongoing Phase 1/2 VBP101 study evaluating trem-cel, or VOR33, followed by Mylotarg in patients with relapsed/refractory AML or MDS in the second half of 2025, the analyst noted.